Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
The US Food and Drug Administration (FDA) and the generic drug industry have reached agreement on some areas amid negotiations to reauthorize the Generic Drug User Fee Amendments (GDUFA IV) program, ...
Stakeholders responding to recent draft guidance from the US Food and Drug Administration (FDA) on the use of minimal ...
The European Medicines Agency has finalized its reflection paper on a tailored clinical approach to biosimilar development, ...
AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion ( STAT) AstraZeneca’s in ...
The US Food and Drug Administration (FDA) has cited a medical device manufacturer and a contract drug testing laboratory for ...
Regulatory Focus is the only source of timely, quality news and information fully dedicated to daily online coverage of the global regulation of healthcare products. An experienced team of reporters ...
The US Food and Drug Administration (FDA) and the generic drug industry have reached agreement on some areas amid ...
A reviewer-informed discussion on managing regulatory submissions across their full lifecycle—from assembly through health ...
The Pharmaceutical Research and Manufacturers of America (PhRMA) has stated that the ICH M4Q(R2) involves a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results